Hookipa Pharma, a Phase 2 biotech developing T cell immunotherapies for cancer and infectious diseases, raised $84 million by offering 6 million shares at $14, the low end of the range of $14 to $16. It had previously filed to offer 6.7 million shares at the same range. Hookipa Pharma plans to list on the Nasdaq under the symbol HOOK. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as lead managers on the deal.
